DCK and acute lymphoblastic leukemia: Other reported attempts in preclinical evaluations include enhancing DCK activity by etoposide in combination with AraC for the treatment of AML,39 and bypassing the drug resistance mechanism associated with downregulated DCK expression using second‐generation deoxyadenosine analog clofarabine in acute lymphoblastic leukemia cells.40